REGENXBIO Inc - Company Profile
Powered by 
All the sales intelligence you need on REGENXBIO Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how REGENXBIO Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with REGENXBIO Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on REGENXBIO Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20230390418A1 | Application | Vectorized factor xii antibodies and administration thereof | C12N15/86; C12N2750/14122; C12N2750/14143; C12N2750/14151; C12N2750/14171; C12N2830/15; A61K48/0041; A61K48/0058; A61K48/0066; A61P7/10; C07K16/36; C07K2317/20 | December 07, 2023 |
| US20230391864A1 | Application | Vectorized anti-tnf-alpha antibodies for ocular indications | C12N15/86; C12N2750/14143; C12N2750/14145; A61P27/02; C07K16/241 | December 07, 2023 |
| EP4284335A1 | Application | Gentherapie für neuronale ceroid-lipofuscinosen | C12N15/86; C12N2750/14143; C12N9/485; C12Y304/14009; A01K2217/075; A01K2227/105; A01K2267/0318; A61K47/02; A61K47/10; A61K47/26; A61K48/005; A61K9/0085; A61K9/08; A61P25/28; C07K14/47 | December 06, 2023 |
| WO2023205610A3 | Application | Hybrid aav capsids | C12N15/86; C12N2750/14122; C12N2750/14143; C12N2750/14145; A61P21/00; C07K14/005; C07K2319/00 | November 30, 2023 |
| AU2022275785A9 | Application | Methods and compositions for treating epilepsy | November 30, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer